Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2022-02-24 00:00:00 ET · period of report 2022-02-22 · accession 0001367644-22-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-24 | 2022-02-22 | EBS | Kramer Robert | Pres, CEO, Dir | A - Grant | $0.00 | +4,264 | 167.3K | +3% | $0 | |
| 2022-02-24 | 2022-02-22 | EBS | Kramer Robert | Pres, CEO, Dir | F - Tax | $42.23 | -4,595 | 162.7K | -3% | -$194.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-22 | A | A | 4,264 | $0.00 | 167,317 | D | — | — | (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 16,065 shares of common stock, which is in excess of the 11,801 shares previously reported on February 28, 2019. |
| 2 | Common | Common Stock | 2022-02-22 | F | D | 4,595 | $42.23 | 162,722 | D | — | — | (F2) Represents shares of common stock withheld to pay taxes. |